前立腺がん診断の世界市場レポート 2025年

前立腺がん診断の市場規模は、今後数年で急成長が見込まれます。2029年には81億7,000万米ドルに成長し、CAGRは12.9％となります。予測期間の成長は、人工知能（AI）の統合、がん検診における遠隔医療の成長、ゲノムプロファイリングの進歩、患者中心のアプローチ、診断のためのマルチパラメトリックMRIなどに起因すると考えられます。予測期間における主な動向としては、リキッドバイオプシー技術、バイオマーカー検出の技術進歩、臨床研究開発、デジタル病理統合、マルチプレックスバイオマーカーアッセイの出現などがあります。

前立腺がん診断市場は、前立腺がんの有病率の増加によって成長が見込まれます。前立腺がんは、男性および女性の生殖器官にある前立腺を侵す疾患で、前立腺特異抗原（PSA）検査や高度な画像診断技術など、さまざまな検査による早期診断が必要です。2023年1月、米国がん協会（ACS）は、同年の前立腺がんの推定新規患者数は288,300人、同疾患に起因する死亡者数は34,700人と報告しました。その結果、前立腺がんの有病率の上昇が前立腺がん診断市場の拡大を促進すると予想されます。

前立腺がん診断市場の成長を牽引しているのは、ヘルスケア支出の増加です。ヘルスケア支出とは、特定の地域、国、組織内のヘルスケア部門に割り当てられる総財源を指します。この支出は、前立腺がん診断のための資源の配分と使用をサポートし、早期発見、正確な病期分類、タイムリーな介入を促進し、患者の転帰、生存率、前立腺がんに罹患した人々のケア全体の質の向上を目指します。例えば、2023年5月、英国の政府部門であるOffice for National Statisticsの報告によると、英国のヘルスケア支出は2022年の0.9％の成長に対し、2022年から2023年にかけて5.6％増加しました。2023年の英国のヘルスケア支出は約3,176億3,000万米ドル（2,920億英ポンド）。このように、ヘルスケア支出の増加が前立腺がん診断市場の今後の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の前立腺がん診断PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の前立腺がん診断市場：成長率分析
• 世界の前立腺がん診断市場の実績：規模と成長, 2019-2024
• 世界の前立腺がん診断市場の予測：規模と成長, 2024-2029, 2034F
• 世界の前立腺がん診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺がん診断市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機器
• 試薬および消耗品
• アクセサリー
• 世界の前立腺がん診断市場：検査タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予備検査
• 確認検査
• 世界の前立腺がん診断市場：前立腺がん別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 扁平上皮がん
• 小細胞がん
• 移行上皮がん
• 前立腺腺がん
• 乳管腺がん
• 小細胞前立腺がん
• 腺房腺がん
• 世界の前立腺がん診断市場：ピアグループ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人用
• 小児科
• 老年医学
• 世界の前立腺がん診断市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 独立診断研究所
• がん調査機関
• その他のエンドユーザー
• 世界の前立腺がん診断市場サブセグメンテーション：機器、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検器具
• イメージングデバイス
• 直腸指診器具
• 世界の前立腺がん診断市場サブセグメンテーション：試薬および消耗品、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断アッセイキット
• 染色試薬
• サンプル収集材料
• 世界の前立腺がん診断市場サブセグメンテーション：アクセサリー、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検ガイド
• 標本取り扱い用アクセサリ
• 校正およびメンテナンスツール

第7章 地域別・国別分析

• 世界の前立腺がん診断市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺がん診断市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺がん診断市場：競合情勢
• 前立腺がん診断市場：企業プロファイル
  • F. Hoffman-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Becton Dickinson and Company
• Agilent Technologies Inc.
• Hologic Inc
• Biomerieux SA
• Beckman Coulter Inc.
• Qiagen N.V.
• EXACT Sciences Corporation
• Diasorin S.P.A.
• OPKO Health Inc.
• Myriad Genetics Inc.
• Cepheid Inc
• NeoGenomics Laboratories Inc.
• Guardant Health Inc
• GRAIL Inc
• Fujirebio Diagnostics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺がん診断市場2029：新たな機会を提供する国
• 前立腺がん診断市場2029：新たな機会を提供するセグメント
• 前立腺がん診断市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Prostate cancer diagnostics involve the process of determining and confirming the presence of prostate cancer through diagnostic testing and medical evaluations. The primary aim is to assess the status and severity of the illness, guiding treatment choices. This diagnostic approach is commonly applied in the treatment of prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

The main products in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories encompass items in the kit that may not be strictly necessary but can enhance effectiveness, such as a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel, all utilized in the diagnosis of prostate cancer. Various test types, including preliminary and confirmatory tests, diagnose different types of prostate cancers, such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostic tests are applicable to various age groups, including adults, pediatric, and geriatric populations, and are performed by different end users, including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $4.43 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to the increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, and improved biopsy techniques

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the integration of artificial intelligence (AI), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and multiparametric MRI for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.

The prostate cancer diagnostics market is anticipated to experience growth, driven by the increasing prevalence of prostate cancer. This condition, affecting the prostate gland in the male and female reproductive systems, necessitates early diagnosis through various tests, including prostate-specific antigen (PSA) testing and advanced imaging techniques. In January 2023, the American Cancer Society (ACS) reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths attributed to the disease for the same year. Consequently, the rising prevalence of prostate cancer is expected to fuel the expansion of the prostate cancer diagnostics market.

The growth of the prostate cancer diagnosis market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the allocation and use of resources for prostate cancer diagnosis, facilitating early detection, accurate staging, and timely intervention, all aimed at improving patient outcomes, survival rates, and the overall quality of care for those affected by prostate cancer. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Thus, the increase in healthcare spending is propelling the growth of the prostate cancer diagnosis market in the future.

Technological innovations represent a prominent trend in the prostate cancer diagnostics market, with major companies introducing advanced AI-powered tools for diagnosis. In March 2023, Qritive, a Singapore-based company, launched QAi Prostate-an AI-powered prostate cancer diagnosis tool designed for pathologists. This tool employs sophisticated machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies. The innovative tool facilitates accurate and swift diagnoses, reducing treatment time.

Strategic partnerships are a key approach adopted by major companies in the prostate cancer diagnostics market to advance cancer precision medicine. In March 2022, Lantheus Holdings Inc., a US-based diagnostic and imaging products company, partnered with Novartis AG, a Switzerland-based pharmaceutical company, to utilize Lantheus' prostate-specific membrane antigen (PSMA) imaging agent, PYLARIFY, in clinical trials for Pluvicto. This collaboration aims to enhance the diagnosis of patients with prostate cancer for improved treatment outcomes.

In August 2022, MDxHealth SA, a US-based precision diagnostics company, acquired Exact Sciences Corporation to bolster its leadership in the precision diagnostics urology market. This acquisition expanded MDxHealth's prostate diagnostics business with the inclusion of the Oncotype DX GPS (Genomic Prostate Score) test. Exact Sciences Corporation, a US-based cancer screening and diagnostic tests company, brought valuable assets, including prostate pipelines software supporting patients throughout their cancer diagnosis and treatment.

Major companies operating in the prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc, Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc, NeoGenomics Laboratories Inc., Guardant Health Inc, GRAIL Inc, Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd, Exosome Diagnostics Inc., Dana-Farber Cancer Institute, Cellanyx Diagnostics Inc., A3P Biomedical AB

North America was the largest region in the prostate cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Products: Instruments; Reagents And Consumables; Accessories
• 2) By Test Type: Preliminary Tests; Confirmatory Tests
• 3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma
• 4) By Peer Groups: Adult; Pediatric; Geriatrics
• 5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutes; Other End-Users
• Subsegments:
• 1) By Instruments: Biopsy Instruments; Imaging Devices; Digital Rectal Examination Tools
• 2) By Reagents And Consumables: Diagnostic Assay Kits; Staining Reagents; Sample Collection Materials
• 3) By Accessories: Biopsy Guides; Specimen Handling Accessories; Calibration And Maintenance Tools
• Companies Mentioned: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Diagnostics Market Characteristics

3. Prostate Cancer Diagnostics Market Trends And Strategies

4. Prostate Cancer Diagnostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Prostate Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Prostate Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate Cancer Diagnostics Total Addressable Market (TAM)

6. Prostate Cancer Diagnostics Market Segmentation

• 6.1. Global Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instruments
• Reagents And Consumables
• Accessories
• 6.2. Global Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preliminary Tests
• Confirmatory Tests
• 6.3. Global Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Squamous Cell Cancer
• Small Cell Carcinoma
• Transitional Cell Cancer
• Prostatic Adenocarcinoma
• Ductal Adenocarcinoma
• Small Cell Prostate Cancer
• Acinar Adenocarcinoma
• 6.4. Global Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatrics
• 6.5. Global Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Other End-Users
• 6.6. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Instruments, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy Instruments
• Imaging Devices
• Digital Rectal Examination Tools
• 6.7. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Reagents And Consumables, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Assay Kits
• Staining Reagents
• Sample Collection Materials
• 6.8. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Accessories, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy Guides
• Specimen Handling Accessories
• Calibration And Maintenance Tools

7. Prostate Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Diagnostics Market

• 8.1. Asia-Pacific Prostate Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Diagnostics Market

• 9.1. China Prostate Cancer Diagnostics Market Overview
• 9.2. China Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Diagnostics Market

• 10.1. India Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Diagnostics Market

• 11.1. Japan Prostate Cancer Diagnostics Market Overview
• 11.2. Japan Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Diagnostics Market

• 12.1. Australia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Diagnostics Market

• 13.1. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Diagnostics Market

• 14.1. South Korea Prostate Cancer Diagnostics Market Overview
• 14.2. South Korea Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Diagnostics Market

• 15.1. Western Europe Prostate Cancer Diagnostics Market Overview
• 15.2. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Diagnostics Market

• 16.1. UK Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Diagnostics Market

• 17.1. Germany Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Diagnostics Market

• 18.1. France Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Diagnostics Market

• 19.1. Italy Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Diagnostics Market

• 20.1. Spain Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Diagnostics Market

• 21.1. Eastern Europe Prostate Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Diagnostics Market

• 22.1. Russia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Diagnostics Market

• 23.1. North America Prostate Cancer Diagnostics Market Overview
• 23.2. North America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Diagnostics Market

• 24.1. USA Prostate Cancer Diagnostics Market Overview
• 24.2. USA Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Diagnostics Market

• 25.1. Canada Prostate Cancer Diagnostics Market Overview
• 25.2. Canada Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Diagnostics Market

• 26.1. South America Prostate Cancer Diagnostics Market Overview
• 26.2. South America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Diagnostics Market

• 27.1. Brazil Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Diagnostics Market

• 28.1. Middle East Prostate Cancer Diagnostics Market Overview
• 28.2. Middle East Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Diagnostics Market

• 29.1. Africa Prostate Cancer Diagnostics Market Overview
• 29.2. Africa Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Diagnostics Market Competitive Landscape
• 30.2. Prostate Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffman-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Becton Dickinson and Company
• 31.2. Agilent Technologies Inc.
• 31.3. Hologic Inc
• 31.4. Biomerieux SA
• 31.5. Beckman Coulter Inc.
• 31.6. Qiagen N.V.
• 31.7. EXACT Sciences Corporation
• 31.8. Diasorin S.P.A.
• 31.9. OPKO Health Inc.
• 31.10. Myriad Genetics Inc.
• 31.11. Cepheid Inc
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Guardant Health Inc
• 31.14. GRAIL Inc
• 31.15. Fujirebio Diagnostics Inc.

32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market

34. Recent Developments In The Prostate Cancer Diagnostics Market

35. Prostate Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Prostate Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer